McCullough Robertson’s Equity Capital Markets and Life Sciences team has successfully assisted Radiopharm Theranostics (ASX: RAD) in raising $10 million, funding its key programs into the end of 2023.

Radiopharm Theranostics is a clinical stage radiotherapeutics company specialising in the development of new radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic uses.

Funds were raised through an accelerated non-renounceable entitlement offer with an institutional component, raising approximately $5.5 million, with Bell Potter Securities Limited fully underwriting the retail component of the entitlement offer of $4.5 million.

Lead Partner, Reece Walker comments “having advised Radiopharm Theranostics on its $50 million IPO in November 2021, we are proud to once again support the team in progressing its further research in this ground-breaking space”.